FORMULATION AND EVALUATION OF REPAGLINIDE IMMEDIATE RELEASE TABLETS WITH IMPROVED DISSOLUTION USING SOLID DISPERSION TECHNIQUE

A Dissertation submitted to
THE TAMIL NADU DR. M.G.R. MEDICAL UNIVERSITY,
CHENNAI - 600 032.

In partial fulfilment of the award of the degree of

MASTER OF PHARMACY
IN
Branch – I – PHARMACEUTICS

Submitted by
Name: P.KARPAGAVALLI
REG.No:261510254

Under the Guidance of
Dr. S. BHAMA, M.Pharm., Ph.D.,
Associate professor,
DEPARTMENT OF PHARMACEUTICS

J.K.K. NATTARAJA COLLEGE OF PHARMACY
KUMARAPALAYAM – 638183.
TAMILNADU.

MAY – 2017
<table>
<thead>
<tr>
<th>S.NO.</th>
<th>CHAPTER</th>
<th>PAGE NO.</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>INTRODUCTION</td>
<td>1</td>
</tr>
<tr>
<td>2</td>
<td>LITERATURE REVIEW</td>
<td>16</td>
</tr>
<tr>
<td>3</td>
<td>AIM AND OBJECTIVE</td>
<td>19</td>
</tr>
<tr>
<td>4</td>
<td>PLAN OF WORK</td>
<td>20</td>
</tr>
<tr>
<td>5</td>
<td>PROFILES</td>
<td>22</td>
</tr>
<tr>
<td>6</td>
<td>MATERIALS AND METHODS</td>
<td>31</td>
</tr>
<tr>
<td>7</td>
<td>RESULTS AND DISCUSSION</td>
<td>43</td>
</tr>
<tr>
<td>8</td>
<td>SUMMARY AND CONCLUSION</td>
<td>80</td>
</tr>
<tr>
<td>9</td>
<td>BIBLIOGRAPHY</td>
<td>82</td>
</tr>
</tbody>
</table>
1. INTRODUCTION

An ideal dosage regimen in the drug therapy of any disease is the one, which immediately attains the desire therapeutic concentration of drug in plasma (or at the site of action) and maintains it constant for the entire duration of treatment. The drug may be administered by variety of routes in a variety of dosage forms. Drugs are more frequently taken by oral administration. The solid dosage forms available mostly in unit dosage forms such as tablets, capsules, lozenges etc¹. When drugs are administered orally in dry state, tablets and capsules are most convenient dosage form². All practical purposes only compression tablets are almost universally used while molded tablets being rate commodity. Drugs are more frequently taken by oral administration³.

Although a few drugs taken orally are intended to be dissolved within the mouth, vast majority of drugs taken oral are swallowed⁴. Compared with alternate routes, the oral route of drug administration is the most popular and has been successfully used for the conventional delivery of drug⁵.

It is considered most natural, uncomplicated, convenient, safe means of administering drugs⁶. Some of its advantages are greater flexibility in dosage design, ease of production and low cost⁷.

Many patients find it difficult to swallow tablets and hard gelatin capsules and thus do not comply with prescription, which results in high incidence of non-compliance and ineffective therapy. Recent advances in novel drug delivery systems (NDDS) aim to enhance the safety and efficacy of drug molecule by formulating a convent dosage form for administration and to achieve better patient compliance⁸.

Nearly 35 - 50% of the general population, especially the elderly and children suffer from dysphasia or difficulty in swallowing, which results in high incidence of non-compliance and ineffective therapy⁹. Swallowing problems also are very common in young individuals because of their poorly developed muscular and nervous systems. Other groups who may experience problems in swallowing conventional oral dosage forms are the patients with tremors of extremities, mentally ill, develop mentally disabled, non-cooperative and patients with reduced liquid intake or patients suffering from nausea, as well as patients travelling or who do not have easy access
to water. The swallowing problems are also common in some cases such as patients with motion sickness, sudden episodes of allergic attack or coughing and due to lack of water.

To overcome this problem, scientists have developed innovative drug delivery system known as a "Immediate release tablets\textsuperscript{10},."

Immediate release tablets are designed to disintegrate and release their medication in absence of any special rate-controlling features as special coating and others techniques\textsuperscript{11}.

1.1 Advantages of Immediate Release Tablets\textsuperscript{12,13,14};

1. Large scale manufacturing is feasible in comparison to other dosage forms, therefore economy can be achieved.

2. Accuracy of dosage is maintained since tablet is a solid unit dosage form.

3. Longer expiry period and microbial spillage owing to lower moisture content.

4. Easy of packaging (blister or strip) and easy handling over liquid a form.

5. Easy to transport in bulk. Emergency supplies can be carried by patients.

6. Easy to transport in bulk. Emergency supplies can be carried by patients\textsuperscript{15}.

7. Product identification is easy and marking done with the help of grooved punched and printing with edible ink,

Disadvantages of Immediate Release Tablets\textsuperscript{16,17};

1. It is difficult to convert a high dose poorly compressible API into tablet of multiple size for human use\textsuperscript{18}.

2. Difficult to formulate a drug with poor wet ability, slow dissolution in to tablet.

3. Slow onsets of action as compared to parenterals, liquid orals are capsules.

4. Difficult to swallow for kids, terminally ill and geriatric patients.

5. Patients undergoing radiotherapy cannot swallow tablet.
1.2. Desired Criteria For Immediate Release Drug Delivery System (IRDS):

Immediate release dissolving tablet should address the following:

- Requires no water for oral administration, but it should dissolve or disintegrate in the mouth in matter of seconds.
- Be compatible with taste masking agent.
- Be portable.
- Have a pleasing mouth feel.
- Leave minimal or no residue in the mouth after oral administration.
- Exhibit low sensitivity to environmental condition as humidity and temperature.
- Allow high drug loading.
- Allow the manufacturing of tablets using conventional processing and packaging equipments at low cost.

1.2.1. Salient Features of Immediate Release Drug Delivery System:

Ease of administration to patient who refuses to swallow a tablet, such as pediatric, geriatric and psychiatric patients.

- Require no water to swallow the dosage form, which is highly convenient feature for patients who are travelling and do not have immediate access to water.
- Rapid dissolution and absorption of drug, which will produce quick onset of action.
- Some drugs are absorbed from the mouth, pharynx and esophagus as the saliva passes down into the stomach; in such cases bioavailability of drug is increased.
- Pregastric absorption can result in improved bioavailability and as a result of reduced dosage; improve clinical performance through a reduction of unwanted effects.

Direct compression is the easiest method to manufacture immediate release tablets (IRTs) and immediate melting tablets (IMTs). The great advantages of direct
compression are its low manufacturing cost. It uses conventional equipment, commonly available excipients and a limited number of processing steps.

Direct compression is the method of choice in tablet manufacture to produce high quality finished product and applied to prepare dispersible tablets\textsuperscript{18}.

In direct compression method, previously only crystalline compounds or materials were considered to be directly compressed, but now the scenarios changing and this technique is being applied for many non-crystalline materials too. Formulations constituted by <-25\% w/w of drug material are easy to be directly compressed by simply using diluents, which are easy to be compressed and which acts as a carrier for the drug\textsuperscript{19}.

**1.2.2. FACTORS AFFECTING THE DRUG RELEASE**\textsuperscript{20}:

1. Physiochemical properties of drug and
2. Dosage form factors

The various physiochemical properties of drug that effect drug dissolution and its rate are - solubility, partical size, polymorphism, salt form, pseudo-polymorphism, complexation, wetability etc.

Dosage form factors include manufacturing process and excipients incorporated in them\textsuperscript{21}.

Several manufacturing process influence drug dissolution form. Processes of such importance in manufacturing of tablets are;

1. Method of granulation
2. Compression force.

The excipients such as binders, lubricants, disintegrants, etc influence the drug dissolution\textsuperscript{26}.

The techniques used in the preparation of immediate release tablets:

**1.3. Conventional Techniques**\textsuperscript{22,23,24}:

1. **Tablet moulding**:

In this method, the delivery system is prepared in the form of tablets using
water soluble additives to allow the tablet to dissolve rapidly and completely in mouth. All the ingredients of the formulation are passed through fine mesh dry bended, wetted with a hydro - alcoholic solvent and then compressed into tablets using low compression forces. The solvent is then removed by air drying.

2. Freezing drying:

Lyophilisation is a pharmaceutical manufacturing technology, which allows drying of heat sensitive drugs and biological at low temperature under conditions that allow removal of water by sublimation. Lyophilization results in preparations which are highly porous, with a very high specific surface area, which dissolve rapidly a show improved absorption and bioavailability.

3. Spray drying:

Spray drying is a process by which highly porous, fine powders can be produced. The composition contains a bulking agent (mannitol and lactose), a disintegrate (sodium starch glycol ate and caramelize sodium), an acidic ingredient (citric acid) and / or alkaline ingredients (sodium bicarbonate) which when compressed into tablets show fast disintegration and enhanced dissolution.

4. Sublimation:

This method includes the addition of a sublime of a sublime salt to the table ting components, compressing the blend and removing the salt by the process of sublimation. The active ingredient, diluents, a sublime salt (camphor / ammonium bicarbonate) a binder and other excipient are blended and tablets are prepared.

5. Addition of disingredients:

Addition of disingredients in immediate release tablets, leads to quick disintegration of tablets and hence improves dissolution. Microcrystalline cellulose, cross-linked carboxy methyl cellulose sodium, cross-linked polyvinyl pyrolidine and partially substituted hydroxy propel cellulose, absorb water and swell due to capillary action and are considered as effective disintegrates in the preparation of immediate releasing tablets.
6. Sugar based excipient:

Sorbitol, mannitol, dextrose, xylitol, fructose, maltose and polydextrose have been used as abulking agents. Because of their high aqueous solubility and sweetness, which impart a pleasing mouth feel and good taste masking, nearly all formulations for rapidly dissolving tablets contain sugar based materials.

7. Mass Extrusion:

This technology involves softening the active blend using the solvent, mixture of water soluble polyethylene glycol using methanol and explosion of softened mass through the extruder or syringe to get a cylinder of the product and cutting into even segments upon heated blade to form tablets.

Patented Technologies:

8. Zydis:

In zydis technology, drug is added to a solution carrier material (preferably gelatin) to obtain dispersion, and the dispersion is filled into performed pockets of blister pack by automatic means and freeze dried to produce the final dosage form.

9. Orasolv:

The system essentially make tablets that contain the taste masked active ingredients an effervescent disintegrating agent, which on contact with saliva, rapidly disintegrates and releases the active ingredient. The tablets are made by direct compression at very low compression forces in order to minimize oral dissolution time. The tablets produced are soft and friable.

10. Durasolv:

The tablet made by this technology consists of a drug, filler and a lubricant. Dura Solve tablets are prepared by using conventional tableting equipment and have good rigidity.

11. Flash dose:

Flash dose tablets consist of self-binding shear form matrix termed as "floss". Shear form materials are prepared by flash heat processing and are of two types.
• Single floss

• Dual floss

1.4. SUPER DISINTEGRANTS

Disintegrates have a major in the disintegration and dissolution process of or dispersible tablets made by direct compression. The choice of a suitable type and optimal amount of disintegrant is important for ensuring high disintegration rate. The addition of other formulation components such as water soluble excipient or effervescent agents further enhance dissolution or disintegration properties. The understanding of disintegrant properties and their effect on formulation has advanced significantly during last few years practically regarding superdisintegrants.

Addition of super disintegrates in ODTs leads to quick disintegration of tablets and hence improves dissolution. Microcrystalline cellulose, crosslinked carboxy methyl cellulose sodium, crosslinked Polyvinyl pyrrolidone and partially substituted hydroxy propyl cellulose etc absorb water and swell due to capillary action and are considered as effective disintegrants in the preparation immediate release of tablets.

1.4.1. MECHANISM OF SUPERDISINTEGRANTS

The tablet breaks to primary particles by one or more of the mechanism listed below.

1. Because of heat of wetting (air expansion):

When disintegrates with exothermic properties gets wetted, localized stress is generated due to capillary air expansion, which helps in disintegration of tablet. This explanation however, is limited to only a few types of disintegrates and cannot describe the action of most modern disintegrating agents.

2. Swelling:

The most widely used mechanism of action for tablet disintegration is swelling. Tablets with high porosity show poor disintegration due to lack of adequate swelling force. swelling force is exerted in the tablet with low porosity.
3. Porosity and capillary action (Wicking):

The first step for this is disintegration by capillary action. The tablet will be put into the suitable aqueous medium; the medium penetrates into the tablet and replaces the air adsorbed on the particles. Which uptake by tablet depends upon hydrophilicity of the drug/excipient and on tableting conditions.

4. Due to disintegrating particle/particle repulsive forces:

Another mechanism of disintegration attempts to explain the swelling of tablet made with “non-swellable” disintegrates. Guyot – Hermann has proposed a particle repulsion theory based on the observation that non-swelling particle also cause disintegration of tablets.

5. Due to deformation:

During tablet compression, disintegrated particles get deformed and those deformed particles get into their normal structure when they come in contact with aqueous media or water. The swelling capacity of starch was improved when granules were extensively deformed during compression. This increase in size of the deformed particles produce produces a breakup of the tablet. This type of mechanism of starch has been recently to be studied.

6. Due to release of gases:

Carbon dioxide released within tablets on wetting due to interaction between bicarbonate with citric acid or tartaric acid. The tablet disintegrates due to generation of pressure within the tablet.

**Table No 1: List of Superdisintegrants**

<table>
<thead>
<tr>
<th>Super disintegrants</th>
<th>Examples</th>
<th>Mechanism of action</th>
</tr>
</thead>
<tbody>
<tr>
<td>Croscarmellose®</td>
<td>Cross Linked Cellulose</td>
<td>Swelling and Wickling</td>
</tr>
<tr>
<td>Crospovidone</td>
<td>Cross linked PVP</td>
<td>Very little swelling, act by capillary action.</td>
</tr>
<tr>
<td>Sodium starch glycolate</td>
<td>Cross linked starch</td>
<td>Swelling</td>
</tr>
</tbody>
</table>
### Chapter 1

**Introduction**

<table>
<thead>
<tr>
<th>Alginic acid NF</th>
<th>Cross linked Alginic acid</th>
<th>Rapid swelling and wicking action</th>
</tr>
</thead>
<tbody>
<tr>
<td>Natural super disintegrants</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Calcium silicate(20 – 40%)</td>
<td></td>
<td>Wicking action</td>
</tr>
</tbody>
</table>

#### 1.5. Techniques for Solubility Enhancement

There are various techniques available to improve the solubility of poorly soluble drugs, some of the approaches to improve the solubility are:

**1. Physical Modification:**

A. Particle size reduction
   
   a. Micronization
   
   b. Nanosuspension

B. Modification of the crystal habit
   
   a. Polymorphs
   
   b. Pseudopolymorphs

C. Drug dispersion in carriers
   
   a. Eutectic mixtures
   
   b. Solid dispersions
   
   c. Solid solutions

D. Complexation
   
   a. Use of complexing agents

E. Solubilization by surfactants:
   
   a. Microemulsions
   
   b. Self microemulsifying drug delivery systems

**2. Chemical Modifications**
1.6. Solid dispersion Technique:

40 - 60% of drugs used in pharmaceutical industry are poorly water soluble or lipophilic compounds. Poorly water soluble drugs show unpredictable absorption, since their bioavailability depends upon dissolution in the GIT. The dissolution characters of poorly water soluble drugs can be enhanced by several methods like pH adjustment, salt formation, co-crystallization, co-grinding, cosolvency, hydrotrophy, solubilization, size reduction like micronization, nano technology, complexation, and drug dispersion in carriers. The solid dispersion can be prepared by fusion method, melting method, solvent method, Hot meltextrusion method and Supercritical fluid method.

a. Fusion Method:

The fusion method is sometime otherwise called as melting method, if the starting material is crystalline. In this method, the carrier is heated to a temperature just above its melting point and the drug is incorporated in to the matrix. The first dispersion of sulfathiazole and urea was prepared by fusion method, by melting at the eutectic composition followed by cooling step. Polymers like Polyethylene glycols and Poly (vinyl pyrolidone) PVP are mostly used in this method.

Limitations:

- This method is suitable if the drug and polymer are compatible and can be mixed homogeneously at the heating temperature in order to prevent formation of two incompatible liquids phases or a suspension in heated mixture. This problem can be overcome by using surfactants.

- Sometimes this problem during cooling stage when the drug – matrix miscibility changes which may produce phase separation. This problem is observed when cooling is done at slow rate, resulting in formation of crystalline drug.

- This method is not suitable if the carrier is high – melting solid and the drug is heat sensitive.
b. Hot melt extrusion method:

This method is same as fusion method except that the intensive mixing is included by the extruder. In this method twin – screw extruder or single extruder is used. This method offers the potential to shape the heated mixture in to implants, implants inserts, oral dosage forms. To detect the solid – state solubility and to select matrix suitable for melt extrusion, the solubility parameters are investigated. Higher shear forces resulting in high temperature in extruder may create a problem for heat sensitive materials.

The main advantage is the handling of product is easier because at the outlet of the extruder the shape can be adapted to the next processing step without grinding. The polymers like Hydroxypropyl cellulose, Hydroxypropyl cellulose phthalate, Eudragit, Celulose acetate phthalate (CAP), Poly vinyl alcohol (PVA), and Hydroxypropyl cellulose (HPC) can be used. Leing Wang, et al., have prepared solid dispersion of Nitredipine with silica particles using the melt mixing method

\[31\]

c. Solvent method:

In this method, the carrier and the active ingredients are dissolved in suitable organic solvent. The second step involves the removal of solvent(S) under vacuum. When the solvent evaporates, super saturation may occur followed by simultaneous precipitation of the constituents resulting in a solid residue. In this formulation the scientist has to face two challenges.

- It is difficult to mix drug and polymer in one solution having different polarity.
- It is difficult to prevent phase separation during removal of solvent(s).
- The recovery of solvent from co precipitate takes longer time.

Example:

Ethanol:-5 C and reduced pressure followed by drying for 12h in vacum Methanol / chloroform: 115 C for 1hr 125 C for 25min from Grisofulvin – PEG 6000 dispersion.

Drying at high temperature speeds up the drying process and reduces the time available for phase separation. On the other hand, high temperature speeds up the
Chapter 1

Introduction

phase separation (example: crystallization) because of the increase in the mobility of drug and polymer.

For example: Dimethyl sulfoxide (DMSO) has high melting point (190°C) but it has very low vapour pressure (0.08 kPa) hence not suitable solvent, but 2-methyl-2-propanol or tertiary butanol (TBA) is suitable solvent because it has high melting point (125°C) and vapor pressure (5.49 kPa).

Advantages:

Minimal thermal stress during preparation.

Reduction in chances of phase separation.

d. Supercritical fluid method:

In this method carbon dioxide is used either as solvent for drug and polymer or as an anti-solvent. When carbon dioxide is used as a solvent, the solution mixture of carbon dioxide with drug and polymer is sprayed through nozzle into an expansion vessel with lower pressure and resulting in formation of particles. As this techniques does not involve use of any organic solvent termed as “Solvent free technique” and also known as Rapid Expansion of Supercritical Solution (RES).

1.6.1. Advantages of Solid Dispersion Technology:

- Single formulation can be used to multiple dose formulation
- Improves bioavailability of drug.
- Improves dissolution of poorly water soluble drugs.
- Controlled release formulations can be formulated.

1.6.2. Breakthrough in Solid Dispersion Technology:

Recently, the primary goal of pharmaceutical industry is to discover a new chemical entity that would be safe and effective. Initially, because of the limited bulk drug supply and accelerated time line would not allow formulator to formulate solid dispersion formulations. Even though, the below two recent breakthroughs in the formulation of solid dispersion technology have renewed the interest for use in commercial development of drug product32, 33.
The development of technology to fill solid dispersion directly into hard gelatin capsules. For example: Chatham prepared PEG-based solid dispersion by filling drug-PEG melts in hard gelatin capsules followed by solidification at room temperature. The availability of surface-active and self-emulsifying carriers For example: Gelucire 44/14, Polysorbate 80.

The availability of surface-active and self-emulsifying agent may help to increase bioavailability of the drug.

➢ For example: The bioavailability of ritronavir (solubility<1mcg/ml at pH.2) [Norvir®, Abbot Lab] was enhanced by incorporating dispersion into mixture of surfaceactive carriers as Gelucire 50/13, Polysorbate 80, and Polyoxy 35 castor oil.

Table No 2: Commercially immediate release Tablets

<table>
<thead>
<tr>
<th>Technologies</th>
<th>Trade Name</th>
<th>Active Ingredient</th>
<th>Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Freeze Drying</td>
<td>Feldene Fast Melt</td>
<td>Piroxicam</td>
<td>Pfizer, USA</td>
</tr>
<tr>
<td></td>
<td>Claritin Red i Tab</td>
<td>Loratidine</td>
<td>Schering plough, USA</td>
</tr>
<tr>
<td></td>
<td>Maxalt MLT</td>
<td>Rizatriptan</td>
<td>Merck, USA</td>
</tr>
<tr>
<td></td>
<td>Z Yprexia</td>
<td>Olanzapine</td>
<td>Eli Lilly, USA</td>
</tr>
<tr>
<td></td>
<td>Pepcid RPD</td>
<td>Famotidine</td>
<td>Merck, USA</td>
</tr>
<tr>
<td></td>
<td>Zofran ODT</td>
<td>Ondansetron</td>
<td>Glaxo, UK</td>
</tr>
<tr>
<td></td>
<td>Zooming ZMT</td>
<td>Zolmitriptan</td>
<td>AstraZeneca, USA</td>
</tr>
<tr>
<td></td>
<td>Zelapar TM</td>
<td>Selegilline</td>
<td>Amarin, UK</td>
</tr>
<tr>
<td>Disintegrant Addition</td>
<td>Tempra Quicklets</td>
<td>Acetaminophen</td>
<td>Bristol Myers, USA</td>
</tr>
<tr>
<td></td>
<td>Febrectol</td>
<td>Paracetamol</td>
<td>Prographarma, France</td>
</tr>
<tr>
<td></td>
<td>Nimulid MDT</td>
<td>Nimesulide</td>
<td>Panacea Biotech, India</td>
</tr>
<tr>
<td></td>
<td>Torrox MT</td>
<td>Rofecoxib</td>
<td>Torrent pharma, India</td>
</tr>
<tr>
<td></td>
<td>Olanex Instab</td>
<td>Olanzapine</td>
<td>Ranbaxy, India</td>
</tr>
<tr>
<td></td>
<td>Romilast</td>
<td>Montelukast</td>
<td>Ranbaxy, India</td>
</tr>
<tr>
<td>Sugar Based Excipient</td>
<td>Benadryl Fastmelt</td>
<td>Diphenhydramine &amp; Pseudoephedrine</td>
<td>WarnerLambert, USA</td>
</tr>
</tbody>
</table>
1.7. ANTI-DIABETIC 34

Repaglinide is a meglinide analogue used in the treatment of type II Diabetes mellitus.

It controls high blood sugar levels and helps in preventing kidney damage, blindness, nerve problems, loss of limbs, sexual problems & heart complications. This should not be used in type I Diabetes mellitus. It is a poorly water soluble drug belongs to BCS class II drug with short biological half-life 1hr. Repaglinide was enhanced by solid dispersion techniques like 1) drop melt techniques. Repaglinide dispersion was selected based on dissolution and formulated as tablet dosage form using various diluents and super disintegrates. The final; formulation was selected based on the dissolution profile that is formulation with MCC as a diluents and cross povidone as a super disintegrants.

1.7.1. Diabetes mellitus type 2 35,36,37:

Diabetes mellitus type 2 (formely calle non-insulin dependent diabetes mellitus(NIDDM), or adult- onset diabetes) is a disorder that is high blood glucose in the context of insulin resistance and relative insulin deficiency. It is often initially managed by increasing exercise and dietary modification; medications are typically needed as the disease progresses.

1.7.2. Signs and symptoms38

- Early symptoms may be nothing more than chronic fatigue, generalized weakness and malaise
- Excessive urine production.
- Excessive thirst and increased fluid intake.
- Blurred vision
- Unexplained weight loss.
- Lethargy.
1.7.3. Classification of Antidiabetic agent

1. Insulin

2. Oral antidiabetic drugs
   a) Sulfonylureas
      I. First - generation agents
         a. Tolbutamide
         b. Acetohexamide
         c. Tolazamide
         d. Chlorpropamide
      II. Second - generation agents
         a. Glipizide
         b. Glyburide
         c. Glimepride
         d. Gliclazide
   b) Meglitinides
      I. Repaglinide
      ii. Nateglinide
   c) Biguanides
      I. Metformin
      II. Phenformin
      III. BUformin
2. LITERATURE REVIEW

D. Karthikeyan et al\textsuperscript{39}, investigated the feasibility of formulating a biphasic delivery system using mini-tablets in hard gelatin capsules delivering drug with a variety of release profiles. Aceclofenac (NSAID analgesic) were chosen as model drug.

Noorana Tehseen et al\textsuperscript{40}, worked on design and characterization of twice daily mini-tablets formulation of pregabalin in order to improve the half life and bioavailability.

Carla M. Lopes et al\textsuperscript{41}, developed compressed mini tablets as a biphasic delivery system designed for zero-order sustained drug release. The outer layer that fills the void spaces between the mini-tablets was formulated to release the drug in a very short time (immediate release), while the mini-tablets provided a prolonged release. Different composition (HPMC or EC) and number (10 or 21) of mini-tablets were used to obtain different drug release rates. Based on the release kinetic parameters calculated, it can be concluded that mini-tablets containing HPMC were particularly suitable approaching to zero-order (constant) release over 8 h time periods.

Intender Joshi et al\textsuperscript{42}, developed a once-daily sustained release matrix tablet of repaglinide using sodium alginate as release controlling factor. In order to achieve required sustained release profile tablets were compressed using sodium CMC, sodium alginate, Magnesium stearate, and PVP. Six different formulation of repaglinide were prepared by using different ratio of drug: polymer. The tablet was characterized by hardness, wetting time, weight variation and In Vitro Drug Release which shows the satisfactory result. All batches of solid matrix tablets were satisfactory in terms of dissolution profile. The batches of all formulations, MT5 batch [Sodium CMC With drug (1:3)] showed more release than the other concentration and better results.

Bhatti et al\textsuperscript{43} prepared fast dissolving tablets of diazepam and provided it`s advantages and evaluation methods.
C. Malligarruna Shetty et al\textsuperscript{44} described the formulation of fast dispersible aceclofenac tablets and described the Effect of functionality of super disintegrants.

Caramella et al\textsuperscript{45} described the role of swelling property in the disintegration process also described how it influences the disintegration process.

Cirri M et al\textsuperscript{46} formulated fast dissolving tablets of Glyburide based on ternary solid dispersion with PEG6000 and surfactants.

Sarasija Suresh et al\textsuperscript{47} prepared mouth dissolving tablets of salbutamol sulphate by using sublimable ingredients. Selection of the filter also had an important role in deciding of the disintegration time. Evaluation of the tablets showed that all the tablets were found to be within official limits and the disintegration time for the formulations ranged from 5s to 4s. Amongst all, the formulation containing microcrystalline cellulose and ammonium bicarbonate showed the least disintegrating time of 5s.

USPTO Patent 20601657821\textsuperscript{48} described about orally disintegrating tablets for per oral administration which disintegrate quickly in the cavity of mouth, in particular less than 30 seconds and the process of obtaining them.

Kaushik D et al\textsuperscript{49}, studied mouth dissolving tablets emerged at an alternative to conventional oral dosage forms. Freeze drying, sublimation, spray drying, disintegrant addition, tablet moulding and use of sugar-based excipients are the techniques available for the formulation of mouth dissolving tablets. Despite the different mechanisms involved in these techniques, the aim is, to provide the tablet that quickly disintegrates or dissolves upon contact with saliva and also provides a good mouth feel.

Zhao et al\textsuperscript{50} described the development of disintegrating functionality test for super disintegrants, also provides methods to test the efficiency of superdisintegrants.

Koizumi et al\textsuperscript{51}, described about rapidly saliva tablets using sublimation technique. Compressed tablets of mannitol did not dissolve in water due to the low porosity. To increase the porosity of tablets sublimation was done. Tablets were prepared by direct compression containing mannitol and camphor. A high porosity was achieved due to formation of many pores due to camphor sublimation. The
compressed tablets have high porosity (approximately 30%) rapidly dissolved within 15 seconds in saliva.

Combo P et al\textsuperscript{52} described about disintegration force, showed disintegration force is a new formulation parameter.

D.P.Venkadesh et al\textsuperscript{53} formulated taste masked orodispersible tablets of ambroxxol hydrochloride.

Ferrari F et al\textsuperscript{54} provided the information about influences of porosity and solubility of disintegrant in tablets.

Caramella et al\textsuperscript{55} described the role of swelling property in the disintegration process also described how it influences the disintegration process.

Jeevana Jyothi et al\textsuperscript{56} developed immediate release tablets of glibenclamide using crosspovidone and its Kneading Mixture.

M M Patel et al\textsuperscript{57} prepared rapid disintegrating tablets of valdecoxib by using various superdisintegrants following direct compression technique.

Martin et al\textsuperscript{58}, reviewed the cyclodextrin and their uses. It provides information regarding the history preparation, complex formation of cyclodextrins and industrial applications.

Pisal et al\textsuperscript{59} formulated and evaluated tasteless complexes of ciprofloxacin with Iodine 234. Studies showed that complication affected by pH, but temperature not affected. Volunteers rated the complex as tasteless.
3. AIM AND OBJECTIVE

The aim of the present work is to investigate the possibility of obtaining immediate release tablet of repaglinide with improved dissolution using Solid dispersion technique.

Basic goals in the immediate release tablets are to increase patient compliance, ease of administration, safety and appropriate dosing. Orally disintegrating formulations are provide benefits for pharmaceutical companies like lifecycle management, line extension, market expansion, cost effective drug development programs.

Immediate release tablet has perceived faster onset of action. repaglinide is a white or half white powder, relatively insoluble in water. It is a class 2 drug according to BCS Classification Solubility and dissolution was improved by formulating solid dispersion. The advantage of this delivery system, in the present study were made to formulate immediate release tablet repaglinide, which is useful to reduce sudden increased glucose level in the treatment of non-insulin dependent diabetes mellitus (NIDDM).

The direct compression was used to compress the tablets as it is easy way to manufacture tablets. Conventional equipments, commonly available excipients and limited number of processing steps are involved in direct compression and so manufacturing cost is low. Tablets produced by direct compression are relatively strong and hardness and have less friability.
4. PLAN OF WORK

Stage – 1

- Literature Survey
- Selection of Drug and Excipients

Stage - 2

Preformulation Studies

- Evaluation of Physical Parameters of repaglinide
- Drug Excipients Compatibility study
- Construction of standard curve

Stage – 3

- Preparation of Solid Dispersion and Physical Mixture
- Characterization of Solid Dispersion and Physical Mixture

Stage – 4

- Preparation And Evaluation of Natural Superdisintegrants

Stage – 5

**Precompression Parameters**

- Formulation of Immediate Release Tablets With Different super Disintegrants

Stage – 6

**Evaluation of Immediate Tablets.**

- Weight variation
- Friability
- Thickness
- Hardness
disintegration

Wetting time

Uniformity of dispersion

Water absorption ratio

Assay

*In-vitro* dissolution study

**Stage – 7**

- Stability Study of optimised formulation as per ICH Guidelines
5. PROFILES

5.1. DRUG PROFILE:

REPAGLINIDE:

PRANDIN® (repaglinide) is an oral blood glucose-lowering drug of the meglitinide class used in the management of type 2 diabetes mellitus (also known as non-insulin dependent diabetes mellitus or NIDDM).

CHEMICAL NAME:

Repaglinide, S (+) 2-ethoxy-4(2-(3-methyl-1-(2-(1-piperidinyl) phenyl)-butyl) amino)-2-oxoethyl) benzoic acid, is chemically unrelated to the oral sulfonylurea insulin secretagogues.

Chemical Structure:

The structural formula is as shown below:

![Chemical Structure Diagram]

Molecular Weight: 452.6

Category: (β) cells in the pancreatic islets.

Description: white to off – white.


Mechanism of Action

Repaglinide lowers blood glucose levels by stimulating the release of insulin from the pancreas. This action is dependent upon functioning beta (β) cells in the
pancreatic islets. Insulin release is glucose-dependent and diminishes at low glucose concentrations.

Repaglinide closes ATP-dependent potassium channels in the β-cell membrane by binding at characterizable sites. This potassium channel blockade depolarizes the β-cell, which leads to an opening of calcium channels. The resulting increased calcium influx induces insulin secretion. The ion channel mechanism is highly tissue selective with low affinity for heart and skeletal muscle.

**Pharmacokinetics**

**Absorption:**

After oral administration, repaglinide is rapidly and completely absorbed from the gastrointestinal tract. After single and multiple oral doses in healthy subjects or in patients, peak plasma drug levels (Cmax) occur within 1 hour (Tmax). Repaglinide is rapidly eliminated from the blood stream with a half-life of approximately 1 hour. The mean absolute bioavailability is 56%. When repaglinide was given with food, the mean Tmax was not changed, but the mean Cmax and AUC (area under the time/plasma concentration curve) were decreased 20% and 12.4%, respectively.

**Distribution:**

After intravenous (IV) dosing in healthy subjects, the volume of distribution at steady state (Vss) was 31 L, and the total body clearance (CL) was 38 L/h. Protein binding and binding to human serum albumin was greater than 98%.

**Metabolism:**

Repaglinide is completely metabolized by oxidative biotransformation and direct conjugation with glucuronic acid after either an IV or oral dose. The major metabolites are an oxidized dicarboxylic acid (M2), the aromatic amine (M1), and the acyl glucuronide (M7). The cytochrome P-450 enzyme system, specifically 2C8 and 3A4, have been shown to be involved in the N-dealkylation of repaglinide to M2 and the further oxidation to M1. Metabolites do not contribute to the glucose-lowering effect of repaglinide.
Excretion:

Within 96 hours after dosing with 14C-repaglinide as a single, oral dose, approximately 90% of the radiolabel was recovered in the feces and approximately 8% in the urine. Only 0.1% of the dose is cleared in the urine as parent compound. The major metabolite (M2) accounted for 60% of the administered dose. Less than 2% of parent drug was recovered in feces.

It indicate that repaglinide did not accumulate in serum. Clearance of oral repaglinide did not change over the 0.5 - 4 mg dose range, indicating a linear relationship between dose and plasma drug levels.

Variability of Exposure:

Repaglinide AUC after multiple doses of 0.25 to 4 mg with each meal varies over a wide range. The intra-individual and inter-individual coefficients of variation were 36% and 69%, respectively. AUC over the therapeutic dose range included 69 to 1005 ng/mL*hr, but AUC exposure up to 5417 ng/mL*hr was reached in dose escalation studies without apparent adverse consequent

5.2.EXCIPIENT PROFILE:

**CROSS POVIDONE**

- **Synonyms**: Crosslinkedpovidone ; EI 202 ; Kollidon CL ; Kollidon CL-M;polyplasdon XL 10 ; Polyvinyl poly pyrrolidone ; PVPP ; 1-vinyl -2- pyrrolidone homopolymeress or nearly odourless hygroscopic powder.

- **Description**: Crospovidone is a white to creamy white finely devided, free Flowing practically tasteless, odorless

- **Chemical name**: 1-ethenyl -2 – pyrrolidone homopolymer.

- **Molecular weight**: >1000000

- **Functional category**: Tablet disintegrant
Applications in Pharmaceutical Formulation

Cross povidone is a water-insoluble tablet disintegrant and dissolution agent used at 2-5% concentration in tablet prepared by direct compression method (1-6). It rapidly exhibit high capillary activity and pronounced hydration capacity, with little tendency to form gels. Studies suggest that the particle size of crospovidone strongly influences disintegration of analgesic tablets.

**SODIUM STARCH GLYCOLATE**

**Synonyms:** Primojel; Starch carboxy Methyl ether, sodium salt, Tablo;

**Description:** Tasteless, free flowing powder. The PhEur 2005 states that it consist of oval or spherical granules, 30-100 μm in diameter, with some less spherical granules ranging from 10-35μm in diameter.

**Chemical name:** Sodium carboxy methyl starch.

**Molecular weight:** 5 X 10^5 -1

**Functional category:** Tablet and capsule disintegrant.

Applications in Pharmaceutical Formulation

Sodium starch glycolate is widely used in oral pharmaceuticals as a disintegrant in capsule and tablet formulations. It is commonly used in tablets prepared by either direct compression or wet granulation process. The usual concentration employed in a formulation is between 2% and 8% with the optimum concentration about 4% although in many cases 2% is sufficient. Disintegration occurs by rapid uptake of water followed by rapid and enormous swelling.

Although the effectiveness of many disintegrant is affected both presence of hydrophobic excipients such as lubricant the disintegrant efficiency of sodium starch glycolate is unimpaired increasing the tablet compression pressure also appears to have no effect on disintegration time. Sodium starch glycolate has also been investigated for use as a suspending vehicle.
CARBOXY METHYL CELLULOSE CALCIUM\textsuperscript{60}

Synonyms : Calcium CMC ; ECG 505 ; Nymcel ZSC ; Calcium Carboxy methyl cellulose

Description : It occurs as a white to yellowish- white hygroscopic fine powder

Chemical name : Cellulose, carboxy methyl ether, calcium salt

Functional category : Stabilizing agent, suspending agent, tablet and capsule disintegrant; tablet binder; viscosity increasing agent Water Absorbing agent.

Application in Pharmaceutical Formulation

It used as binder, diluents and disintegrant. It is an effective disintegrant as it swells to several times its original bulk on contact with water. Concentration up to 15 % w/w may be used in tablet formulations; above this concentration, tablet hardness is reduced.

It is also used as suspending or viscosity increasing agent in oral and topical formulations. And also used in modern wound dressings for its water absorption, retension and hemostatic properties.

SODIUM STEARYL FUMERATE\textsuperscript{60}

Synonyms : Fumeric acid, Otadecyl ester sodium salt; Pruv ; Sodium monosrearylfumerate.

Description : Sodium stearylfumerate is a fine white powder with agglomerates of flat, circular shaped particles.

Chemical name : 2-butenedioic acid, monoocadecyl ester, sodium salt.

Molecular weight : 390.5

Functional category : Tablet and capsule lubricant.

Applications in Pharmaceutical Formulation

Sodium stearylfumerate is used as lubricant, in capsule and tablet formulations at 0.5 – 2.0 % w/w concentration. It is also used in certain food applications conditioning or stabilizing agent in various backery Products, flour-thickened foods, dehydrated potatoes and processed cereal up to 0.2-1.0 % by weight of the food.
TALC 61

Synonyms: talc; E 55 3 b; hydrous magnesium calcium silicate; hydrous magnesium Silicate; magnesium hydrogen metasilicate; Magsilosmanthus; magsil star; powdered talc; purified French chalk; Purtalc; soapstone; steatite; superior.

Description: Talc is very fine to grayish-white, odorless, impalatable, unctuous, crystalline powder. It adheres readily to the skin and is soft to touch and free from grittiness.

Chemical name: Talc

Functional category: Anticaking agent; glidant; tablet and capsule diluents;

Applications in pharmaceutical formulation

Talc was once widely used in oral solid dosage formulations as a lubricant and diluent although today it is less commonly used. It is widely used as dissolution retardant in the development of controlled release product. Talc is used as a lubricant in tablet formulations; in novel powder coating for extended-release pellets; and as an adsorbent.

In topical preparations, talc is used as a dusting powder, although it should not be used to dust. Surgical gloves. As it is a natural material it may contain microorganisms and should be sterilized when used as dusting powder. Talc used to clarify liquids and is also used in cosmetics and food products, mainly for its lubricant properties

POLYETHYLENE GLYCOL 600060

Synonyms: Breox peg; carbowax; hodag peg; lutrol E; PEG: polyethylene glycol.

Description: Polyethylene glycols grades 6000 and above are available as free-flowing milled powders, colorless or slightly yellow colored. They have a slight, but characteristic odour and a bitter, slightly burning taste.

Chemical name: \( \alpha \)-hydro-\( \omega \)-hydro- poly (oxy-1, 2- ethane diyl) and [25322-68-3]

Molecular weight: 5000 – 7000 (average molecular weight)
Typical properties:

1. Density; 1.15–1.21 g/cm$^3$ at 25°C.
2. Melting Point: 55–63°C
3. pH (5% w/v solution): 4.0-7.0.

Incompatibilities:

All grades can exhibit some oxidizing activity due to the presence of peroxide impurities and some secondary product formed by auto-oxidation. Solid polyethylene glycols grades may be incompatible with some colour.

Safety:

Nontoxic and non-irritant material, when administered topically may cause stringing.

Application in pharmaceutical formulation:

Polyethylene glycols can also be used to enhance the aqueous solubility or dissolution characteristics of poorly soluble compounds by making solid dispersions with an appropriate polyethylene glycol. Animal studies have also been performed using polyethylene glycols as solvents for steroids in osmotic pumps.

MICROCRYSTALLINE CELLULOSE$^{60}$

Nonproprietary Names:

- BP: Microcrystalline cellulose
- JP: Microcrystalline cellulose
- PhEur: Cellulosummicrocrystallinum
- USPNF: Microcrystalline cellulose

Synonyms:

Cellulose gel;; crystalline cellulose; E460;; Fibrocel;; Tabulose.
Chemical Name and CAS Registry Number:

Cellulose [9004-34-6]

Empirical Formula and Molecular Weight:

\[(\text{C}_6\text{H}_{10}\text{O}_5)_n \approx 36000 \]

where \( n \approx 220 \).

Structural Formula:

![Cellulose Structural Formula](image)

Functional Category:

Adsorbent; suspending agent; tablet and capsule diluents; tablet disintegrant.

Applications in Pharmaceutical Formulation or Technology:

Microcrystalline cellulose is widely used in pharmaceuticals, primarily as a binder/diluents in oral tablet and capsule formulations where it is used in both wet-granulation and direct-compression processes. In addition to its use as a binder/diluents (20–90%), microcrystalline cellulose also has some lubricant and disintegrant (5–15%) properties that make it useful in tableting.

Description:

Microcrystalline cellulose is purified, partially depolymerized cellulose that occurs as a white, odorless, tasteless, crystalline powder composed of porous particles. It is commercially available in different particle sizes and moisture grades that have different properties and applications.
Density (bulk)

- 0.337 g/cm$^3$;
- 0.32 g/cm$^3$ for Avicel PH-101; 0.29 g/cm$^3$ for Emcocel 90M; 0.29 g/cm$^3$ for VivaPur 101.

Density (tapped):

- 0.478 g/cm$^3$;
- 0.45 g/cm$^3$ for Avicel PH-101;
- 0.35 g/cm$^3$ for Emcocel 90M.

Density (true):

- 1.512–1.668 g/cm$^3$

Melting point:

Chars at 260–270°C.

Solubility:

Slightly soluble in 5 % w/v sodium hydroxide solution; practically insoluble in water, dilute acids, and most organic solvents.

Stability and Storage Conditions:

Microcrystalline cellulose is a stable though hygroscopic material. The bulk material should be stored in a well-closed container in a cool, dry place.
6. MATERIALS AND METHODS

MATERIALS USED

List of Materials used for the research work was given in table by:

**TABLE NO. 3**

<table>
<thead>
<tr>
<th>INGREDIENTS</th>
<th>SUPPLIERS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Repaglinide</td>
<td>Microlabs Ltd, Hosur</td>
</tr>
<tr>
<td>PEG6000</td>
<td>Microlabs Ltd, Hosur</td>
</tr>
<tr>
<td>Micro crystalline cellulose</td>
<td>Lobachemi, Mumbai</td>
</tr>
<tr>
<td>Sodium Starch Glycolate</td>
<td>Research lab fine chem, Mumbai</td>
</tr>
<tr>
<td>Cross Povidone</td>
<td>Research lab fine chem, Mumbai</td>
</tr>
<tr>
<td>Sodium alginate</td>
<td>Lobachemi, Mumbai</td>
</tr>
<tr>
<td>Talc</td>
<td>Lobachemi, Mumbai</td>
</tr>
<tr>
<td>Aspartame</td>
<td>Bangalore antibiotics &amp; Biological, Salem</td>
</tr>
<tr>
<td>Methanol</td>
<td>Himmedialab, Mumbai</td>
</tr>
<tr>
<td>Aerosil</td>
<td>Lobachem, Mumbai</td>
</tr>
<tr>
<td>Hcl</td>
<td>Microlab, Mumbai</td>
</tr>
</tbody>
</table>

**TABLE NO. 4**

List of Instrument Used

<table>
<thead>
<tr>
<th>Name of Instrument</th>
<th>Manufacturing Company</th>
</tr>
</thead>
<tbody>
<tr>
<td>Digital Balance</td>
<td>Shimadzu Corporation Japan</td>
</tr>
<tr>
<td>Magnetic stirrer</td>
<td>Remiequipments</td>
</tr>
<tr>
<td>Hot air oven</td>
<td>In lab equipments, chennai</td>
</tr>
<tr>
<td>Orbit Shaker</td>
<td>Lab India</td>
</tr>
<tr>
<td>Proton Pump Mini Single Punch</td>
<td>Proton</td>
</tr>
<tr>
<td>Hardness tester</td>
<td>Tab machines</td>
</tr>
<tr>
<td>Friability tester</td>
<td>Roche Friabilator</td>
</tr>
<tr>
<td>Vernier caliper</td>
<td>Mituyoko Japan</td>
</tr>
<tr>
<td>Dissolution Apparatus</td>
<td>Lab India Disso 2000</td>
</tr>
<tr>
<td>UV Visible spectrophotometer</td>
<td>Lab India</td>
</tr>
<tr>
<td>FT IR Spectrometer</td>
<td>Bruker Germany</td>
</tr>
<tr>
<td>Disintegration</td>
<td>Rolex</td>
</tr>
</tbody>
</table>
6.1 PRE-FORMULATION STUDIES\textsuperscript{62}:

Preformulation may be described as a phase of the research and development process where the formulation scientist characterizes the physical, chemical and mechanical properties of new drug substances, in order to develop stable, safe and effective dosage forms.

6.1.1 Organoleptic properties:

**Appearance**

Transferred approximately 2gm of the sample on a white paper spreaded uniformly and examined visually.

**Colour:** a small quantity of pure repaglinide powder was taken in a butter paper and viewed in well illuminated place.

**Taste and odour:** very less quantity of repaglinide was used to get taste with the help of tongue as well as smelled to get the odour.

6.1.2 Angle of repose:

Angle of repose has been defined as the maximum angle possible between the surface of pile of powder and horizontal plane. The angle of repose for the granules of each formulation was determined by the funnel method. The prepared granules were allowed to flow out of the funnel orifice fixed at a height of 2 cm from the surface on a plane paper kept on the horizontal platform. The gradual addition of the granules from the funnel mouth forms a pile of granules at the surface this is continued until the pile touches the stem tip of the funnel. A rough circle is drawn around the pile base and the radius of the granule cone was measured.

Angle of repose was then calculated with the use of the following formula:

\[
\tan \theta = \frac{h}{r}
\]

Where, \( \theta \) = angle of repose, \( h \) = height of the pile, \( r \) = average radius of the powder cone.
Limits:

<table>
<thead>
<tr>
<th>Angle of repose</th>
<th>Flow property</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt;25°</td>
<td>Excellent</td>
</tr>
<tr>
<td>25-30°</td>
<td>Good</td>
</tr>
<tr>
<td>30-40°</td>
<td>Passable</td>
</tr>
<tr>
<td>&gt;40°</td>
<td>Very poor</td>
</tr>
</tbody>
</table>

**TABLE NO. 5**

6.1.3: DETERMINATION OF DENSITIES

Bulk Density: Bulk density is defined as the mass of the powder divided by the bulk volume. Bulk density largely depends on particle shape, as the particle become more spherical in shape, bulk density was increased. In addition as the granule size increases bulk density decreases.

**METHODS:**

Bulk density of the sample was determined by pouring gently 10g of sample through a glass funnel into a 50ml graduated cylinder. The volume occupied by the sample was recorded. The bulk density will be calculated as follows:

Bulk Density (g/ml) = Weight of sample in grams / Volume occupied by the sample.

**TAPPED DENSITY:**

10 grams of sample was being poured gently through a glass funnel into a 50ml graduated cylinder. The cylinder will be tapped from height of 2 inches until a constant volume will be obtained. Volume occupied by the sample after tapping will be recorded and tapped density will be calculated as follows:

Tapped Density (grams/ml) = Weight of sample in grams / Volume occupied by the sample.
6.1.4 Measurement of Powder Compressibility:

Based on the apparent bulk and the tapped density, the percentage compressibility of bulk was determined by the following formula

\[
\text{Compressibility index: } \frac{100(V_0 - V_f)}{V_0}
\]

Where, \(V_f\) = final tapped volume, \(V_0\) = initial untapped volume

**Limits:**

<table>
<thead>
<tr>
<th>S. No.</th>
<th>Compressibility index</th>
<th>Flow</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>5-12</td>
<td>Free flow</td>
</tr>
<tr>
<td>2</td>
<td>12-16</td>
<td>Good flow</td>
</tr>
<tr>
<td>3</td>
<td>18-21</td>
<td>Fair</td>
</tr>
<tr>
<td>4</td>
<td>23-25</td>
<td>Poor</td>
</tr>
<tr>
<td>5</td>
<td>33-38</td>
<td>Verypoor</td>
</tr>
<tr>
<td>6</td>
<td>&gt;40</td>
<td>Extremely poor</td>
</tr>
</tbody>
</table>

\[
\text{Hausner Ratio: } = \frac{V_0}{V_f}
\]

Where, \(V_f\) = final tapped volume, \(V_0\) = initial untapped volume

6.1.5 LOSS ON DRYING:

Determine on 1 g by drying in an oven at 100°C to 105°C for 3 hours. Mixed and accurately weighed the substance to be tested. Tare a glass stopper, shallow weighing bottle that has been dried for 30 minutes under the same conditions to be employed in the determination. Weighed the empty bottle (\(W_1\)). Put the sample in bottle, replace the cover, and accurately weighed the empty bottle with contents (\(W_2\)). By gentle, sidewise shaking, distributed the sample as evenly as practicable to a depth of about 5 mm. placed the loaded bottle in the drying chamber. Dried the sample at the specified temperature in desiccator before weighing. Weighed the bottle (\(W_3\)). The difference between successive weights should not less than 0.3%.
The loss on drying is calculated by the formula:

\[
\% \text{ LOD} = \frac{(W_2 - W_3)}{(W_2 - W_1)} \times 100
\]

Where,  
\( W_1 = \) Weight of empty weighing bottle 
\( W_2 = \) Weight of weighing bottle + sample 
\( W_3 = \) Weight of weighing bottle + dried sample

### 6.1.6 SOLUBILITY ANALYSIS:

Solubility is an important pre-formulation parameter because it affects the dissolution of drug, bio availability of drug, less soluble in water, solubility of repaglinide was determined in methanol, ethanol, dimethyl fluoride methylchloride, 0.1NHCl. Solubility studies were performed by taking excess amount of repaglinide in different beakers containing the solvent.

### 6.1.7 pH

Weighed and transferred accurately about 1.0 g of sample in 20 ml clean and dried volumetric flask dissolved in methanol free water and made up the volume to 20 ml with the same solvent, mixed. Determined the pH of freshly prepared solution by using recalibrated pH meter.

### 6.1.8 ASSAY

Weighed accurately 10mg of repaglinide sample and added to 100 ml volumetric flask. Added 1ml of methanol mixed for 10 minutes added 60ml of 0.1 N Hydrochloric acid and dissolved it. Made up the volume to 100ml with 0.1 N Hydrochloric acid. Took 10ml and diluted to 100ml with 0.1 N HCL. Took 1ml and diluted to 10 ml with 0.1 N HCL, absorbance measured at 283nm.

### 6.2 DRUG-EXCIPIENT COMPATIBILITY STUDY BY FTIR

Infra red spectroscopy is one of the most widely used tools for purity analysis of drugs in pharmaceutical Industry. Fourier Transform IR spectra were recorded using bruker Germany. IR spectrophotometer. KBr powder was used to prepare pellet for sampling. The scanning range was 4000- 40cm
6.3 PREPARATION OF STANDARD CURVE

The calibration curve is based on the spectrophotometry. The maximum absorption was observed at 283nm.

The Standard solution in repaglinide in pH acetate buffer 10mg of repaglinide is accurately weighed and dissolved in 10ml containing methanol in a volumetric flask. The various concentrations of repaglinide prepared are 10, 20, 30, 40, 50, 60, ug/ml. The absorbance of various solutions of repaglinide are determined spectrophotometricaaly at 283nm employing UV double beam spectrophotometer using acetate buffer of pH.

6.4 PREPARATION OF SOLID DISPERSION AND PHYSICAL MIXTURE

6.4.1. Solid dispersions prepared by melting the carrier

Solid dispersions (SDs) preparations containing different weight ratios of repaglinide in PEG6000 (1:1, 1:3, 1:5) were prepared by the melting method. repaglinide was added to the melted PEG 6000 at 75°C and the resulting homogenous preparation was rapidly cooled in a freezing mixture of ice and sodium chloride, and stored in desiccators for 24h.Subsequently, the dispersion was ground in a mortar and sieved through 100#

6.4.2. Physical Mixture

Physical mixture (PMs) having the same weight ratios were prepared by thoroughly mixing appropriate amounts of repaglinide and PEG 6000 in a mortar until a homogenous mixture was obtained. The resulting mixture were sieved through a 100# sieve and denoted as PM.

6.5 Characterization of solid dispersions of repaglinide with PEG 6000

6.5.1 Drug content

About 10mg of drug equivalent of physical mixture and solid dispersion (theoretical) were weighed accurately and transferred to 50ml volumetric flask to which 10ml methanol was added and sonicated for 15min and volume was made up with methanol. From this stock solution further dilution were done and assayed using ultraviolet spectrophotometer measured at 283nm.
6.5.2 Phase-Solubility Study

Phase-solubility studies were carried out to evaluate the possible solubilizing effect of the carrier by adding an excess amount of drug to flask containing 10ml of aqueous solutions containing increasing concentrations of PEG6000. The flask were placed in a mechanical shaker at 75rpm and room temperature for 24 hours. After 24 hours the solutions were filtered and analysed by UV-Spectrophotometer at 283nm.

6.5.3 Dissolution Studies:

Dissolution studies of repaglinide in powder form, SDs, and PMs were performed by using the USP type II paddle apparatus at the paddle rotation speed of 75 rpm in 900ml of pH 5 acetate buffers as a dissolution medium at 37±0.5 ºC. The SDs or PMs Equivalent to 2mg of repaglinide was weighed using a digital balance and added into the dissolution medium. At the specified times (every 10 min for 2 hours), 10ml samples were withdrawn by using syringe filter (0.45 µm) and then assayed for repaglinide content by measuring the absorbance at 283 nm using a UV-Visible spectrophotometer. Fresh medium (10ml), which was prewarmed at 37 ºC, was added to the dissolution medium after each sampling to maintain its constant volume throughout the test.

6.5.4. Fourier transforms IR spectroscopy:

Fourier-transform infrared (FT-IR) spectra were obtained by using Bruker Germany FTIR. The samples (repaglinide or SDs or PMs) were previously ground and mixed thoroughly with potassium bromide, an infrared transparent matrix, at 1:5 (Sample/KBr) ratio, respectively. The KBr discs were prepared by compressing the powders at a pressure of 5 tons for 5 min in a hydraulic press.

6.6. Preparation of natural superdisintegrants (plantago ovata seed powder, mucilage and husk powder)\textsuperscript{65}:

The powder of seeds and husk were prepared by an automatic grinder and sieved (#80). Then it stored in a dedicator until use. For isolation of seed mucilage, the cleaned seeds of Plantago ovata were soaked in distilled water 48 hrs and then boiled few minutes so that mucilage was completely released in to water. This material squeezed through muslin cloth for filtering and separating out the marc. Then an equal
volume of acetone was added to the filtrate so as to precipitate the mucilage. The mucilage was dried in oven (less than 60°C), powdered, sieved (# 80) and stored in desiccators until use.

The natural super disintegrants were evaluated for their physicochemical properties. The swelling index is calculated, it is the volume in milliliters that is occupied by 1g of drug or any substance after it has swollen in an aqueous liquid for 4 hr. The physical mixture of drug complex with this super disintegrants was allowed to stand for 7 days and the assay of drug was performed for compatibility studies.

Preparation of the prepared natural super disintegrants were evaluated for swelling factor, bulk density, tapped density, angle of repose. Angle of repose were calculated according to the formula procedure in 6.1.4 bulk density and tapped density were found out using the procedure given compressibility and hausner’s ratio were found out according to the formula 6.1.4.

6.7. FORMULATION OF IMMEDIATE RELEASE TABLETS OF REPAGLINIDE.66

Different repaglinide Immediate Release Tablets were prepared according to the proportions given in the table no 9. The raw materials passed through a screen (# 60). Prior to mixing powdered separately the repaglinide Solid dispersion, and weighed the amount equivalent to 10 mg repaglinide, was mixed with other excipients and compressed proton mini press tablet punching machine. All formulation prepared according to the following formulation table.
FORMULATION OF IMMEDIATE RELEASE TABLET

Table No - 7

<table>
<thead>
<tr>
<th>S. No.</th>
<th>Ingredient Name</th>
<th>F1</th>
<th>F2</th>
<th>F3</th>
<th>F4</th>
<th>F5</th>
<th>F6</th>
<th>F7</th>
<th>F8</th>
<th>F9</th>
<th>F10</th>
<th>F11</th>
<th>F12</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>1:5 Solid Dispersion equivalent to</td>
<td>10</td>
<td>10</td>
<td>10</td>
<td>10</td>
<td>10</td>
<td>10</td>
<td>10</td>
<td>10</td>
<td>10</td>
<td>10</td>
<td>10</td>
<td>10</td>
</tr>
<tr>
<td></td>
<td>2mg Repaglinide</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>Microcrystalline Cellulose</td>
<td>92</td>
<td>92</td>
<td>92</td>
<td>92</td>
<td>92</td>
<td>92</td>
<td>92</td>
<td>92</td>
<td>92</td>
<td>92</td>
<td>92</td>
<td>92</td>
</tr>
<tr>
<td>3</td>
<td>Mannitol</td>
<td>80.0</td>
<td>78.0</td>
<td>80.0</td>
<td>78.0</td>
<td>80.0</td>
<td>78.0</td>
<td>80.0</td>
<td>78.0</td>
<td>80.0</td>
<td>78.0</td>
<td></td>
<td></td>
</tr>
<tr>
<td>4</td>
<td>Ispaghail Mucilage</td>
<td>10</td>
<td>12.0</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>5</td>
<td>Ispaghail Powder</td>
<td>-</td>
<td>-</td>
<td>10.0</td>
<td>12.0</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>6</td>
<td>Ispaghail husk powder</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>10.0</td>
<td>120</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>7</td>
<td>Cross Povidone</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>10.0</td>
<td>12.0</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>8</td>
<td>CMC</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>10.0</td>
<td>12.0</td>
<td></td>
</tr>
<tr>
<td>9</td>
<td>SSG</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>10.0</td>
<td>12.0</td>
<td>-</td>
</tr>
<tr>
<td>10</td>
<td>Talc</td>
<td>2</td>
<td>2</td>
<td>2</td>
<td>2</td>
<td>2</td>
<td>2</td>
<td>2</td>
<td>2</td>
<td>2</td>
<td>2</td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td>11</td>
<td>Aspartame</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>12</td>
<td>Aerosil</td>
<td>4.0</td>
<td>4.0</td>
<td>4.0</td>
<td>4.0</td>
<td>4.0</td>
<td>4.0</td>
<td>4.0</td>
<td>4.0</td>
<td>4.0</td>
<td>4.0</td>
<td>4.0</td>
<td>4.0</td>
</tr>
<tr>
<td>13</td>
<td>Orange Flavour</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td></td>
<td>Total weight</td>
<td>200</td>
<td>200</td>
<td>200</td>
<td>200</td>
<td>200</td>
<td>200</td>
<td>200</td>
<td>200</td>
<td>200</td>
<td>200</td>
<td>200</td>
<td>200</td>
</tr>
</tbody>
</table>

6.8. Evaluation of Immediate Release Tablet:

6.8.1 PHYSICAL APPEARANCE

Prepared immediate release Tablets were evaluated for the smoothness and absence of cracks, chips and other undesirable characteristics

6.8.2 WEIGHT VARIATION

Twenty tablets were randomly selected and weighed to determine the average weight and were compared with individual tablet weight. The percentage weight variation was calculated. As per Indian Pharmacopoeia specification, tablet with an average weight between 80 – 250 mg, percentage deviation should not more than ±0.5 % and the tablet with an average weight more than 250 mg should not be more than ± 10 %.
Tablet weight – Average weight
\[ \text{% Deviation} = \left( \frac{\text{Tablet weight} - \text{Average weight}}{\text{Tablet weight}} \right) \times 100 \]

6.8.3 FRIABILITY

Friability of the tablets was checked by Roche friabilator. In this device, tablets subjected to combined effects of abration and shock by utilizing a plastic chamber that revolves at 75 rpm, dropping the tablets at a distance of 6 inches in each revolution. Pre weighed tablets were placed in friabilator, which was then operated for 100 revolutions. The tablets were dusted and reweighed.

\[ F = \left( \frac{W_0 - W_1}{W_0} \right) \times 100 \]

Where, \( W_0 = \) initial weight, \( W_1 = \) final weight

6.8.4 THICKNESS

The thicknesses were measured using vernier caliper and values were tabulated. Three tablets of each batch were measured. Average and standard deviation was calculated.

6.8.5 HARDNESS

Monsanto hardness tester was used for the determination of hardness. For each formulation 3 tablets were determined.

6.8.6 DISINTEGRATION TIME

A disintegration time of 6 tablet from each formulation was determined by using USP disintegration apparatus. Disintegration test was carried out in 900ml buffer pH 6.8 at 37 ± 2°C and apparatus operated for 3 minutes, six tablets were taken and one tablet was introduced in each tube, disc was placed and basket and the disintegration time in seconds was noted.

6.8.7 WETTING TIME

This is carried out as a measure of hydrophilicity of tablets. Wetting time is a length of time required to wet the tablet. A piece of tissue paper (12 x 10.75) was...
folded twice was placed in the small Petri dish (I.D 6.5cm) containing 6 ml of buffer pH 6.8 simulated to salivary pH, tablet was placed on the paper and time for complete wetting was measured. Three trials of each batch were performed and standard deviation was determined.

**6.8.8 UNIFORMITY OF DISPERSION TEST**

Two tablets from each batch were separately kept in 100 ml water and gently stirred for 2 minutes. The dispersion was passed through 22 mesh. The tablets were considered to pass the test if no residue remained on the screen.

**6.8.9 WATER ABSORPTION RATIO**

Water absorption ratio, which is important criteria for understanding the capacity of disintegrants to swell in the presence of little amount of water. Weight of the tablet after and before the test was taken. Water absorption ratio (R) is calculated using following formula.

\[
R = \frac{W_a - W_b}{W_b} \times 100
\]

Where,

- \( W_a \) = weights of the tablets after water absorption test
- \( W_b \) = weight of the tablets before water absorption test

**6.8.10 ASSAY**

**STANDARD PREPARATION**

Weigh accurately 100 ml volumetric flask, dissolved in minimum quantity of methanol. The volume made up to 100 ml with 0.1 N hydrochloric acid. Took 10 ml of that solution and diluted to 100 ml with 0.1 N hydrochloric acid. Took 1 ml from that solution and diluted to 10 ml with 0.1 N hydrochloric acid.

**SAMPLE PREPARATION**

Mixed well and volume made up to 100ml. Filtered the solution and 10 ml of this solution diluted to 100 ml. From that took 1ml and diluted to 10 ml. Absorbance measured at 283 nm by UV/Visible spectrophotometer.
6.8.11 DISSOLUTION STUDIES

Dissolution studies were carried out using USP type II (paddle apparatus) at 75rpm pH 5 acetate buffer was used as dissolution medium. Temperature was maintained at 37 ±0.5 °C. Aliquots of dissolution media was withdrawn at specific time intervals and it was filtered. Same quantity of fresh media was replaced. The filtered solution was used to determine the estimation of drug content. The absorbances were measured at 283 nm by UV/Visible spectrophotometer. The test was carried out for 30 minutes.

6.8.12 KINETIC STUDY

The release data obtained from optimized formulation was studied further for the fitness of data in different kinetic models like, zero order, first order, Higuchi’s and korsmeyer – Peppa’s.

6.9 ACCELERATED STABILITY STUDIES

Selected formulation were subjected to stability studies as per I.C.H guidelines. Following conditions were used for stability testing. 40°C / 75 % RH analyzed every month for a period of two months as per I.C.H guidelines. By keeping 40 ± 2°C /RH the formula analyzed every month for a period of 3 months.
Chapter 7 Results and Discussion

7. RESULTS AND DISCUSSION

7.1 Preformulation Studies

7.1.1 Organoleptic Properties

These tests were performed as per procedure given in 6.1.1. The results were illustrated in table no. 8.

<table>
<thead>
<tr>
<th>Test</th>
<th>Specification/Limits</th>
<th>Observations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Color</td>
<td>White to half-white powder</td>
<td>White powder</td>
</tr>
<tr>
<td>Odour</td>
<td>Odourless</td>
<td>Odourless</td>
</tr>
</tbody>
</table>

7.1.2 Loss on Drying

This test was done as per procedure stated in 6.1.2. The results were illustrated in table no. 9.

<table>
<thead>
<tr>
<th>Test</th>
<th>Specification/Limits</th>
<th>Observations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Loss on drying</td>
<td>Not more than 0.5%</td>
<td>0.085%</td>
</tr>
</tbody>
</table>

7.1.3 Flow Properties (Angle of repose)

It was determined as per procedure given in 6.1.3. The results were illustrated in tables No. 10.

<table>
<thead>
<tr>
<th>Material</th>
<th>Angle of repose</th>
</tr>
</thead>
<tbody>
<tr>
<td>Repaglinide</td>
<td>27.85˚</td>
</tr>
</tbody>
</table>

*Average of three determinations
7.1.4 Determination of Density

It was determined as per procedure given in 6.1.4. The results were illustrated in table no. 11.

**Table No.11: Density**

<table>
<thead>
<tr>
<th>Material</th>
<th>Bulk Density (gm/ml)</th>
<th>Tapped density (gm/ml)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Repaglinide</td>
<td>0.24</td>
<td>0.35</td>
</tr>
</tbody>
</table>

*Average of three determinations

7.1.5. Powder compressibility

It was determined as per procedure given in 6.1.5. The results were illustrated in table no. 12.

**Table No.12: Powder Compressibility**

<table>
<thead>
<tr>
<th>Materials</th>
<th>Compressibility Index</th>
<th>Hausner Ratio</th>
</tr>
</thead>
<tbody>
<tr>
<td>Repaglinide</td>
<td>14.23%</td>
<td>1.84%</td>
</tr>
</tbody>
</table>

*Average of three determinations

7.1.6. Solubility

It was determined as per procedure given in 6.1.6. The results were illustrated in table no. 13.

**Table No.13: Solubility**

<table>
<thead>
<tr>
<th>Test</th>
<th>Specification</th>
<th>Result</th>
</tr>
</thead>
<tbody>
<tr>
<td>Solubility in water, Methanol, Methylene chloride.</td>
<td>Practically insoluble in water, freely soluble in methylene chloride, soluble in methanol</td>
<td>Complies</td>
</tr>
</tbody>
</table>

Deviations in the text have been corrected for clarity and coherence.
7.1.7 **pH of the solutions**

pH of the solution was determined as per procedure given in 6.1.7. The results were illustrated in table no. 14.

<table>
<thead>
<tr>
<th>Test</th>
<th>Specification</th>
<th>Observation</th>
</tr>
</thead>
<tbody>
<tr>
<td>pH</td>
<td>5.5</td>
<td>5</td>
</tr>
</tbody>
</table>

7.1.8. **Assay**

It was determined as per procedure given in 6.1.8. The results were illustrated in table no. 15.

<table>
<thead>
<tr>
<th>Assay</th>
<th>Specification</th>
<th>Observation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Assay</td>
<td>90.8-101.75 %</td>
<td>101.18 %</td>
</tr>
</tbody>
</table>

7.2 **DRUG EXCIPIENTS COMPATABILITY STUDY BY FTIR;**

Compatibility study was performed using FT-IR spectrophotometer. The IR spectrum of pure drug, physical mixture of drug and excipients were studied by making a KBr pellet.
7.2.1 FTIR Studies

The spectral details for the drug and physical mixtures are shown as follows

FT-IR Peak Of Various Components.

Fig. No. 1: IR spectrum of Repaglinide

Fig. No. 2: Ispagol Mucilage
Fig. No. 3: Ispagol Seed Powder

Fig. No. 4: Ispagol Husk Powder
Fig. No. 5: IR Spectra of Microcrystalline Cellulose

Fig. No. 6: IR Spectra of Crospovidone
Fig. No. 7: IR Spectra of Croscarmellose Sodium

Fig. No. 8: IR Spectra of Sodium Starch Glycolate
Chapter 7 Results and Discussion

Fig. No. 9: IR Spectra of PEG 6000

Fig. No. 10: IR Spectra of Repaglinide & Excipient Mixture
Table No. 16:

<table>
<thead>
<tr>
<th>Characteristic bands</th>
<th>Pure drug</th>
<th>Physical mixture</th>
</tr>
</thead>
<tbody>
<tr>
<td>O-H</td>
<td>3103.54cm⁻¹</td>
<td>3005.14cm⁻¹</td>
</tr>
<tr>
<td>N-H</td>
<td>1599.09cm⁻¹</td>
<td>1739.03cm⁻¹</td>
</tr>
<tr>
<td>C-O</td>
<td>1108.83cm⁻¹</td>
<td>1365.64cm⁻¹</td>
</tr>
<tr>
<td>C=C</td>
<td>3005.90 cm⁻¹</td>
<td>1477.26cm⁻¹</td>
</tr>
<tr>
<td>C-N</td>
<td>2825.87 cm⁻¹</td>
<td>1579.39cm⁻¹</td>
</tr>
</tbody>
</table>

The FT-IR Spectra analysis showed that there is change in percent transmittance which may be due to change in crystallinity and there is no appearance or disappearance of any characteristics peak of pure drug repaglinide and in the physical mixture of drug to polymer, which confirms the absence of chemical interaction between drug and polymer.

7.3. PREPARATION OF STANDARD CURVE

A UV spectrophometric method given in IP is used for dissolution samples of repaglinide tablet. Absorbance scans of drug is pH5 acetate buffer, showed maximum at 283nm, which is selected as the analytical wavelength. Standard curve of repaglinide in Calibration curve of repaglinide was determined by plotting absorbance versus concentration (μg/ml) at 283nm. The results obtained were as follows.

repaglinide standard calibration curve in pH 5 Acetate buffer at 283 nm

Table No. – 17 :

<table>
<thead>
<tr>
<th>Concentration (μg/ml)</th>
<th>Absorbance at 283nm</th>
</tr>
</thead>
<tbody>
<tr>
<td>10</td>
<td>0.121</td>
</tr>
<tr>
<td>20</td>
<td>0.283</td>
</tr>
<tr>
<td>30</td>
<td>0.455</td>
</tr>
<tr>
<td>40</td>
<td>0.651</td>
</tr>
<tr>
<td>50</td>
<td>0.810</td>
</tr>
<tr>
<td>60</td>
<td>0.913</td>
</tr>
</tbody>
</table>
7.4 PREPARATION OF SOLID DISPERSION AND PHYSICAL MIXTURE

As per the method given in 6.4.1 and 6.4.2 solid dispersion and physical mixture were prepared.

7.5 Characterization of solid dispersions of repaglinide with PEG 6000

7.5.1. Drug content

It was determined as per procedure given in 6.5.1. The results were illustrated in table no. 18.

Table No. 18: Drug content in physical mixtures and solid dispersions

<table>
<thead>
<tr>
<th>Solid dispersion (drug to PEG mass ratio)</th>
<th>Drug content (%)</th>
<th>Physical mixture (drug to PEG mass ratio)</th>
<th>Drug content (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>SD 1:1</td>
<td>97.54</td>
<td>PM 1:1</td>
<td>98.05</td>
</tr>
<tr>
<td>SD 1:3</td>
<td>96.25</td>
<td>PM 1:3</td>
<td>97.96</td>
</tr>
<tr>
<td>SD 1:5</td>
<td>98.42</td>
<td>PM 1:5</td>
<td>98.18</td>
</tr>
</tbody>
</table>

Fig. 11: Calibration curve in pH 5 Acetate buffer at 283 nm
7.5.2. Phase solubility Study

It was determined as per procedure given in 6.5.2. The results were illustrated below.

![Absorbance vs Concentration](image)

**Fig. 12 : Solubility diagram of repaglinide in presence of PEG 6000**

Fig no.11 represented the effect of different polymers concentration at different temperature on the solubility of repaglinide. The plots of drug solubility against the polymer concentration at the investigated temperatures indicated a linear relationship between drug solution and polymer concentration. The result shown that in both cases, the solubility of repaglinide increased with increasing temperature and carrier concentration.

Solubility of repaglinide in pure water at 25°C was 0.01 (µg/ml). At the highest polymer concentration (10% w/w), the solubility increased approximately 4 fold for PEG 6000 at 25°C. The same tendency was observed for other temperatures.

7.5.3. Dissolution studies

It was determined as per procedure given in 6.5.3. The results were illustrated in table no. 20.
Table No. 20: *In-vitro* Dissolution Profile of repaglinide Physical Mixture of repaglinide and Solid Dispersion of repaglinide in pH 1.2 Buffers.

<table>
<thead>
<tr>
<th>Sr. No.</th>
<th>Formulation</th>
<th>Percentage drug released after 30 minutes (DR)</th>
</tr>
</thead>
<tbody>
<tr>
<td>A1</td>
<td>Drug</td>
<td>31.23 ± 2.25 %</td>
</tr>
<tr>
<td>A2</td>
<td>PM 1:1</td>
<td>41.54 ± 2.58 %</td>
</tr>
<tr>
<td>A3</td>
<td>PM 1:2</td>
<td>44.86 ± 2.69%</td>
</tr>
<tr>
<td>A4</td>
<td>PM 1:5</td>
<td>51.12 ± 2.50%</td>
</tr>
<tr>
<td>A5</td>
<td>SD 1:1</td>
<td>87.89 ± 2.25 %</td>
</tr>
<tr>
<td>A6</td>
<td>SD 1:2</td>
<td>93.46 ± 2.35%</td>
</tr>
<tr>
<td>A7</td>
<td>SD 1:5</td>
<td>98.35 ± 2.76%</td>
</tr>
</tbody>
</table>

**Fig. 12: Comparison of *in-vitro* dissolution profile of formulation A1-A7**

The percentage release of repaglinide at various time intervals from the physical mixtures and solid dispersions made by using various concentration.

The percentage release of repaglinide at various time intervals from the physical mixtures and solid dispersions made by using various concentrations of PEG 6000 are shown in Fig.no.11. From table no.20 it is evident that onset of dissolution of pure repaglinide is very low, about 31.23% of drug being dissolved within 30 min. In the 30 minutes, physical mixtures of PEG 6000 (1:1, 1:2 and 1:5) showed 41.54, 44.86 and 51.12% drug release, and 87.89, 93.46, and 98.35 % drug release from solid dispersions (1:1, 1:2 and 1:5).SDs of repaglinide with PEG 6000 considerably enhanced dissolution rates within 30 min compared to pure repaglinide and PMs.

**7.5.4 Fourier transforms IR spectroscopy**

It was determined as per procedure given in 6.5.4. The following figures were illustrated results.
Fig. No. 13: IR Spectra of Repaglinide

Fig. No. 14: IR Spectra of Solid dispersion 1:1
Fig. No. 15: IR Spectra of Physical mixture 1:1

Fig. No. 16: IR Spectra of Solid dispersion 1:3
Fig. No. 17: IR Spectra of Physical mixture 1:3

Fig. No. 18: IR Spectra of Solid dispersion 1:5
The IR spectra of SDs and PMs were compared with the standard spectrum of repaglinide. IR spectrum of repaglinide was characterized by the absorption of carbonyl (C-O) group at 1108.83 cm$^{-1}$. In spectra of SDs and PMs, this band was shifted towards higher frequencies at 3005.14 and 2,825.87 cm$^{-1}$ respectively. Also the O-H group which is located at 3,103.54 cm$^{-1}$ from the IR spectrum of repaglinide, N-H group at 1599.09, C=C group at 3005.90, C-N group at 2825.87 It was concluded that there was no well defined chemical interaction between repaglinide and PEG 6000 in SDs and in PMs, as no important new peaks could be observed.

**7.6. Preparation And Evaluation Of Natural Superdisintegrants**

Natural super disintegrates were prepared and evaluated according to the procedure given in 6.6.
Table No. 21: Preliminary evaluation of natural superdisintegrants

<table>
<thead>
<tr>
<th>Parameters</th>
<th>Mucilage</th>
<th>Seed Powder</th>
<th>Husk Powder</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bulk Density (gm/cm$^3$)</td>
<td>0.96</td>
<td>0.50</td>
<td>1.17</td>
</tr>
<tr>
<td>Tapped Density (gm/Cm$^3$)</td>
<td>1.08</td>
<td>0.91</td>
<td>1.35</td>
</tr>
<tr>
<td>Hausner’s Ratio</td>
<td>1.083</td>
<td>1.14</td>
<td>1.11</td>
</tr>
<tr>
<td>Compressibility index (%)</td>
<td>6.58</td>
<td>15.37</td>
<td>14.66</td>
</tr>
<tr>
<td>Angle of Repose ($^\circ$)</td>
<td>25.20</td>
<td>40.36</td>
<td>33.15</td>
</tr>
</tbody>
</table>

7.7. FORMULATION OF REPAGLINIDE IMMEDIATE RELEASE TABLET

According to the formula given in table No. 8, repaglinide immediate release tablet were formulated and before formulation pre-compression parameters were evaluated and given in table no. 22.

Table No: 22 Precompression parameters

<table>
<thead>
<tr>
<th>Parameters</th>
<th>F1</th>
<th>F2</th>
<th>F3</th>
<th>F4</th>
<th>F5</th>
<th>F6</th>
<th>F7</th>
<th>F8</th>
<th>F9</th>
<th>F10</th>
<th>F11</th>
<th>F12</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bulk density</td>
<td>0.360</td>
<td>0.370</td>
<td>0.310</td>
<td>0.310</td>
<td>0.32</td>
<td>0.330</td>
<td>0.350</td>
<td>0.370</td>
<td>0.350</td>
<td>0.330</td>
<td>0.32</td>
<td></td>
</tr>
<tr>
<td>Tapped density</td>
<td>0.450</td>
<td>0.440</td>
<td>0.430</td>
<td>0.420</td>
<td>0.43</td>
<td>0.440</td>
<td>0.410</td>
<td>0.440</td>
<td>0.45</td>
<td>0.43</td>
<td>0.41</td>
<td></td>
</tr>
<tr>
<td>% Compressibility</td>
<td>15.36</td>
<td>15.07</td>
<td>21.64</td>
<td>20.15</td>
<td>20.85</td>
<td>20.47</td>
<td>16.64</td>
<td>16.56</td>
<td>17.35</td>
<td>18.13</td>
<td>18.81</td>
<td>17.65</td>
</tr>
<tr>
<td>Hausner’s Ratio</td>
<td>1.185</td>
<td>1.11</td>
<td>1.25</td>
<td>1.23</td>
<td>1.24</td>
<td>1.21</td>
<td>1.20</td>
<td>1.43</td>
<td>1.17</td>
<td>1.26</td>
<td>1.36</td>
<td>1.26</td>
</tr>
</tbody>
</table>

7.8. EVALUATION OF IMMEDIATE RELEASE TABLETS

7.8.1. TABLET PHYSICAL APPEARANCE

The tablets were evaluated for their physical properties like color uniformity, presence of cracks, chipping, etc. No undesirable properties were found out.
7.8.2. WEIGHT VARIATION TEST

It was determined as per procedure given in 6.8.2. The results were illustrated in table No. 23.

7.8.3. FRIABILITY

The friability test were carried out according to the procedure given in 6.8.3. The result was tabulated in the Table No. 24.

7.8.4. THICKNESS

The thickness was carried out according to the procedure given in 6.8.4. The result was tabulated in the table No.23.

7.8.5. HARDNESS (KG/CM$^2$)

The Hardness tests were carried out according to the procedure given in 6.8.5. The result was tabulated in the table No.23.

7.8.6. DISINTEGRATION TEST (IN SEC.)

It was determined as per procedure given in 6.8.6 the results were illustrated in table No.23. The results indicated that the disintegration time of tablets was within 35 seconds.

7.8.7. WETTING TIME

It was determined as per procedure given in 6.8.7. The results were illustrated in table 23.

7.8.8. TEST FOR UNIFORMITY OF DISPERSION

It was determined as per procedure given in 6.8.8. The results were illustrated in table No.23.

7.8.9. WATER ABSORPTION RATIO

The test is conducted according to the procedure given in 6.8.9. To measure the hydrophilicity of tablets, the results were illustrated in the table No.23.

7.8.10 ASSAY

It was determined according to the procedure given in 6.8.10. The percent purity was determined by UV method, the results were illustrated in the table No.23.
**Table No.23: EVALUATION CHART OF TABLET**

<table>
<thead>
<tr>
<th>S.No</th>
<th>Parameter</th>
<th>Formulation Code</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>F1</td>
</tr>
<tr>
<td>1</td>
<td>Weight Variation Test</td>
<td>198.66±0.23</td>
</tr>
<tr>
<td>2</td>
<td>% Friability</td>
<td>0.26</td>
</tr>
<tr>
<td>3</td>
<td>Thickness (mm)</td>
<td>2.58±0.01</td>
</tr>
<tr>
<td>4</td>
<td>Hardness (Kg / cm²)</td>
<td>2.06±0.10</td>
</tr>
<tr>
<td>5</td>
<td>Disintegration Time (sec)</td>
<td>23.36±2.6</td>
</tr>
<tr>
<td>6</td>
<td>Wetting time (sec)</td>
<td>50.69±1.6</td>
</tr>
<tr>
<td>8</td>
<td>W.A.Ratio (%)</td>
<td>65.46</td>
</tr>
<tr>
<td>9</td>
<td>Assay (%)</td>
<td>99.48</td>
</tr>
</tbody>
</table>
7.5.11 IN-VITRO DISSOLUTION STUDIES

Dissolution study carried out according to procedure given in 6.8.11. The study or 30 minutes, the results were illustrated in the table below.

**Table No.24: Dissolution profile of formulation F1**

<table>
<thead>
<tr>
<th>Time In Minute</th>
<th>Cummulative Percent Drug Release(%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>5</td>
<td>78.45</td>
</tr>
<tr>
<td>10</td>
<td>80.92</td>
</tr>
<tr>
<td>15</td>
<td>84.76</td>
</tr>
<tr>
<td>20</td>
<td>89.15</td>
</tr>
<tr>
<td>25</td>
<td>93.82</td>
</tr>
<tr>
<td>30</td>
<td>97.92</td>
</tr>
</tbody>
</table>

**Fig. No. 20. In-vitro dissolution study F1**
Chapter 7  Results and Discussion

Table No.25: Dissolution profile of formulation F2

<table>
<thead>
<tr>
<th>Time in Minute</th>
<th>Cumulative Percent Drug Release (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>5</td>
<td>78.72</td>
</tr>
<tr>
<td>10</td>
<td>81.45</td>
</tr>
<tr>
<td>15</td>
<td>84.50</td>
</tr>
<tr>
<td>20</td>
<td>90.00</td>
</tr>
<tr>
<td>25</td>
<td>94.37</td>
</tr>
<tr>
<td>30</td>
<td>99.50</td>
</tr>
</tbody>
</table>

Fig. No. 21. *In-vitro* dissolution study F2
Table No.26: Dissolution profile of formulation F3

<table>
<thead>
<tr>
<th>Time in minute</th>
<th>Percent Drug Release (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>5</td>
<td>79.82</td>
</tr>
<tr>
<td>10</td>
<td>82.02</td>
</tr>
<tr>
<td>15</td>
<td>85.03</td>
</tr>
<tr>
<td>20</td>
<td>90.52</td>
</tr>
<tr>
<td>25</td>
<td>94.91</td>
</tr>
<tr>
<td>30</td>
<td>98.75</td>
</tr>
</tbody>
</table>

Fig. No. 22. *In-vitro* dissolution study F3
### Table No.27: Dissolution profile of formulation F4

<table>
<thead>
<tr>
<th>Time in Minute</th>
<th>Cumulative Percent Drug Release (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>5</td>
<td>80.37</td>
</tr>
<tr>
<td>10</td>
<td>82.30</td>
</tr>
<tr>
<td>15</td>
<td>85.85</td>
</tr>
<tr>
<td>20</td>
<td>91.90</td>
</tr>
<tr>
<td>25</td>
<td>94.95</td>
</tr>
<tr>
<td>30</td>
<td>98.23</td>
</tr>
</tbody>
</table>

**Fig. No. 23. In-vitro dissolution study F4**
Table No.28: Dissolution profile of formulation F5

<table>
<thead>
<tr>
<th>Time in minute</th>
<th>Cumulative Percent Drug Release (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>5</td>
<td>81.47</td>
</tr>
<tr>
<td>10</td>
<td>84.50</td>
</tr>
<tr>
<td>15</td>
<td>86.14</td>
</tr>
<tr>
<td>20</td>
<td>90.10</td>
</tr>
<tr>
<td>25</td>
<td>94.15</td>
</tr>
<tr>
<td>30</td>
<td>98.05</td>
</tr>
</tbody>
</table>

Fig. No. 24. *In-vitro* dissolution study F5
Table No.29: Dissolution profile of formulation F6

<table>
<thead>
<tr>
<th>Time in minute</th>
<th>Cumulative Percent Drug Release (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>5.0</td>
<td>84.75</td>
</tr>
<tr>
<td>10</td>
<td>86.69</td>
</tr>
<tr>
<td>15</td>
<td>89.15</td>
</tr>
<tr>
<td>20</td>
<td>93.25</td>
</tr>
<tr>
<td>25</td>
<td>97.39</td>
</tr>
<tr>
<td>30</td>
<td>98.87</td>
</tr>
</tbody>
</table>

Fig. No. 25. *In-vitro* dissolution study F6
Table No.30: Dissolution profile of formulation F7

<table>
<thead>
<tr>
<th>Time in minute</th>
<th>Cumulative Percent Drug Release (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>5.0</td>
<td>82.58</td>
</tr>
<tr>
<td>10</td>
<td>85.05</td>
</tr>
<tr>
<td>15</td>
<td>57.24</td>
</tr>
<tr>
<td>20</td>
<td>90.53</td>
</tr>
<tr>
<td>25</td>
<td>95.73</td>
</tr>
<tr>
<td>30</td>
<td>99.35</td>
</tr>
</tbody>
</table>

Fig. No. 26. *In-vitro* dissolution study F7
Table No. 31: Dissolution profile of formulation F8

<table>
<thead>
<tr>
<th>Time in minute</th>
<th>Cumulative Percent Drug Release (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>5.0</td>
<td>80.37</td>
</tr>
<tr>
<td>10</td>
<td>82.15</td>
</tr>
<tr>
<td>15</td>
<td>85.46</td>
</tr>
<tr>
<td>20</td>
<td>89.11</td>
</tr>
<tr>
<td>25</td>
<td>94.15</td>
</tr>
<tr>
<td>30</td>
<td>99.65</td>
</tr>
</tbody>
</table>

Fig. No. 27. *In-vitro* dissolution study F8
Table No.32: Dissolution profile of formulation F9

<table>
<thead>
<tr>
<th>Time in minute</th>
<th>Percent Drug Release (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>5.0</td>
<td>83.23</td>
</tr>
<tr>
<td>10</td>
<td>86.17</td>
</tr>
<tr>
<td>15</td>
<td>88.55</td>
</tr>
<tr>
<td>20</td>
<td>92.70</td>
</tr>
<tr>
<td>25</td>
<td>96.05</td>
</tr>
<tr>
<td>30</td>
<td>98.41</td>
</tr>
</tbody>
</table>

Fig. No. 28. *In-vitro* dissolution study F9
Table No.33: Dissolution profile of formulation F10

<table>
<thead>
<tr>
<th>Time in minute</th>
<th>Cumulative Percent Drug Release (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>5.0</td>
<td>84.76</td>
</tr>
<tr>
<td>10</td>
<td>86.70</td>
</tr>
<tr>
<td>15</td>
<td>89.19</td>
</tr>
<tr>
<td>20</td>
<td>93.29</td>
</tr>
<tr>
<td>25</td>
<td>96.40</td>
</tr>
<tr>
<td>30</td>
<td>97.50</td>
</tr>
</tbody>
</table>

Fig. No. 29. In-vitro dissolution study F10
Table No.34: Dissolution profile of formulation F11

<table>
<thead>
<tr>
<th>Time in minute</th>
<th>Cumulative Percent Drug Release (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>5.0</td>
<td>83.85</td>
</tr>
<tr>
<td>10</td>
<td>86.05</td>
</tr>
<tr>
<td>15</td>
<td>89.24</td>
</tr>
<tr>
<td>20</td>
<td>91.55</td>
</tr>
<tr>
<td>25</td>
<td>95.75</td>
</tr>
<tr>
<td>30</td>
<td>98.35</td>
</tr>
</tbody>
</table>

Fig. No. 30. *In-vitro* dissolution study F11
Table No.35: Dissolution profile of formulation F12

<table>
<thead>
<tr>
<th>Time in minute</th>
<th>Cumulative Percent Drug Release (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>5.0</td>
<td>83.81</td>
</tr>
<tr>
<td>10</td>
<td>87.17</td>
</tr>
<tr>
<td>15</td>
<td>88.65</td>
</tr>
<tr>
<td>20</td>
<td>92.60</td>
</tr>
<tr>
<td>25</td>
<td>96.15</td>
</tr>
<tr>
<td>30</td>
<td>98.99</td>
</tr>
</tbody>
</table>

Fig. No. 31. In-vitro dissolution study F12
Table No: 36 Comparative dissolution study F 1 – F 12.

<table>
<thead>
<tr>
<th>Time</th>
<th>F1</th>
<th>F2</th>
<th>F3</th>
<th>F4</th>
<th>F5</th>
<th>F6</th>
<th>F7</th>
<th>F8</th>
<th>F9</th>
<th>F10</th>
<th>F11</th>
<th>F12</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>5</td>
<td>78.45</td>
<td>78.72</td>
<td>79.82</td>
<td>80.37</td>
<td>81.47</td>
<td>84.75</td>
<td>82.58</td>
<td>80.37</td>
<td>83.23</td>
<td>84.76</td>
<td>83.85</td>
<td>83.81</td>
</tr>
<tr>
<td>10</td>
<td>80.92</td>
<td>81.45</td>
<td>82.02</td>
<td>82.30</td>
<td>84.50</td>
<td>86.69</td>
<td>85.05</td>
<td>82.15</td>
<td>86.17</td>
<td>86.70</td>
<td>86.05</td>
<td>87.17</td>
</tr>
<tr>
<td>15</td>
<td>84.76</td>
<td>84.50</td>
<td>85.03</td>
<td>85.85</td>
<td>86.14</td>
<td>89.15</td>
<td>87.24</td>
<td>85.46</td>
<td>88.55</td>
<td>89.19</td>
<td>89.24</td>
<td>88.65</td>
</tr>
<tr>
<td>20</td>
<td>89.15</td>
<td>90.00</td>
<td>90.52</td>
<td>91.90</td>
<td>93.25</td>
<td>90.53</td>
<td>89.11</td>
<td>92.70</td>
<td>93.29</td>
<td>91.55</td>
<td>92.60</td>
<td></td>
</tr>
<tr>
<td>25</td>
<td>93.82</td>
<td>94.37</td>
<td>94.91</td>
<td>94.35</td>
<td>94.15</td>
<td>97.39</td>
<td>95.73</td>
<td>94.15</td>
<td>96.05</td>
<td>96.40</td>
<td>95.75</td>
<td>96.15</td>
</tr>
<tr>
<td>30</td>
<td>97.92</td>
<td>99.50</td>
<td>98.75</td>
<td>98.23</td>
<td>98.05</td>
<td>98.87</td>
<td>99.35</td>
<td>99.65</td>
<td>98.41</td>
<td>97.50</td>
<td>98.35</td>
<td>98.99</td>
</tr>
</tbody>
</table>

Fig. No. 32. Comparison of In-vitro dissolution profile of formulation F1-F12
7.8.12. KINETIC STUDY OF OPTIMIZED FORMULATION

*In-vitro* release data was flattened in different kinetic model and given in table 37 and figure 33 to 36.

### Table No. 37 Kinetic data of Optimized Formulation F2

<table>
<thead>
<tr>
<th>Time</th>
<th>Log time</th>
<th>$\sqrt{Time}$</th>
<th>Cumulative % drug release</th>
<th>Log cumulative % drug release</th>
<th>Cumulative % drug remained</th>
<th>Log cumulative % drug remained</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>100</td>
<td>2.00</td>
</tr>
<tr>
<td>5</td>
<td>0.698</td>
<td>2.23</td>
<td>78.72</td>
<td>1.89</td>
<td>21.28</td>
<td>1.32</td>
</tr>
<tr>
<td>10</td>
<td>1.0</td>
<td>3.16</td>
<td>81.45</td>
<td>1.91</td>
<td>18.55</td>
<td>1.26</td>
</tr>
<tr>
<td>15</td>
<td>1.176</td>
<td>3.87</td>
<td>84.50</td>
<td>1.92</td>
<td>15.50</td>
<td>1.19</td>
</tr>
<tr>
<td>20</td>
<td>1.301</td>
<td>4.47</td>
<td>90.00</td>
<td>1.95</td>
<td>10.00</td>
<td>1.00</td>
</tr>
<tr>
<td>25</td>
<td>1.397</td>
<td>5.0</td>
<td>94.37</td>
<td>1.97</td>
<td>5.63</td>
<td>0.75</td>
</tr>
<tr>
<td>30</td>
<td>1.477</td>
<td>5.477</td>
<td>99.50</td>
<td>1.99</td>
<td>0.50</td>
<td>0.30</td>
</tr>
</tbody>
</table>

**Fig. No. 33 : ZERO ORDER**

$$y = 2.416x + 39.25$$  
$$R^2 = 0.586$$
Fig. No. 34: FIRST ORDER

Log Cumulative% Drug Release vs Time (Min)

\[ y = 0.044x + 1.000 \]
\[ R^2 = 0.421 \]

Fig. No. 35: HIGUCHI

Cumulative Percent Drug Release vs √Time

\[ Y = 15.47X + 12.97 \]
\[ R^2 = 0.925 \]
The above studies showed that the drug release follows first order kinetics.

7.9. STABILITY STUDY

Optimized formulation (F2) was subjected to stability studies at 40°C ± 2°C/75% RH ± 5% for 90 days. The product was evaluated for appearance and hardness, friability, disintegration. Drug release studies were conducted as per the planned schedule as above.

7.9.1. Descriptions:

Table No. 38: Description

<table>
<thead>
<tr>
<th>Storage condition</th>
<th>Test</th>
<th>Observation</th>
<th>Inference</th>
</tr>
</thead>
<tbody>
<tr>
<td>RT</td>
<td>Descriptions</td>
<td>No change of color in all strengths</td>
<td>Complies with stability condition</td>
</tr>
<tr>
<td>40°C + 2°C/75% RH</td>
<td>Descriptions</td>
<td>No change of color in all strengths</td>
<td>Complies with stability condition</td>
</tr>
</tbody>
</table>

7.9.2. Stability parameters of formulation F2 stored at 40°C + 2°C/75% RH

The results were illustrated in following table no. 39.
Table No.39:

<table>
<thead>
<tr>
<th>Sr. No.</th>
<th>Parameters</th>
<th>Initial</th>
<th>30 days</th>
<th>60 days</th>
<th>90 days</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>% Friability</td>
<td>0.20</td>
<td>0.27</td>
<td>0.270</td>
<td>0.273</td>
</tr>
<tr>
<td>2</td>
<td>Hardness (kg / cm²)</td>
<td>2.6</td>
<td>2.5</td>
<td>3.1</td>
<td>3.2</td>
</tr>
<tr>
<td>3</td>
<td>Drug Content (%)</td>
<td>100.01</td>
<td>99.10</td>
<td>98.51</td>
<td>98.21</td>
</tr>
<tr>
<td>4</td>
<td>In-Vitro Disin. Time(Sec)</td>
<td>21.05</td>
<td>21.15</td>
<td>23.24</td>
<td>24.11</td>
</tr>
</tbody>
</table>

All results complies with the stability condition

7.9.3. In-vitro Dissolution study

It was done as per procedure given in material and method part. The results were illustrated in following table no. 45.

Storage Condition at 40°C + 2°C

Table No.40: In-vitro dissolution study

<table>
<thead>
<tr>
<th>Formulation (F2)</th>
<th>Percentage Drug Release After 30 minutes</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Initial (0Days)</td>
</tr>
<tr>
<td></td>
<td>99.50</td>
</tr>
</tbody>
</table>

The results showed that there was no significant change in physical and chemical parameter of the tablet, hence the formulation was found to be stable.
Fig. No. 37: *In-vitro* dissolution study F2 dissolution studies
8. SUMMARY AND CONCLUSION

SUMMARY

In the present study immediate release drug delivery system of repaglinide were successfully developed in the form of mouth dissolving tablets with improved dissolution characteristic by forming solid dispersion with PEG 6000, which offers a suitable and practical approach in serving desired objective of faster disintegration and dissolution characteristics with increase bioavailability. Immediate release tablets of repaglinide were prepared by using natural superintegrants like microcrystalline cellulose, croscarmellose sodium, crospovidone, sodium starch glycolate and their combination as superdisintegrants.

Superdisintegrants work as an auxiliary or as a facilitator of the flowability and compressibility of the mixture and contribute to the immediate release of the tablet, due to its high solubility in water.

For the repaglinide formulation, batch No. 2 was chosen as it has disintegration time around 5-35 seconds and hardness 3.5 Kg/Cm². IR spectra of drug with other excipients has not shown any interaction and also selected formulation was stable after stability studies.

CONCLUSION

The solubility and dissolution rate of repaglinide can be enhanced by formulating SDs of repaglinide with PEG 6000. The solubilization effect of PEG 6000, reduction of particle aggregation of the drug, formation of microcrystalline or amorphous drug, increased wetability and dispersibility, and alteration of the surface properties of the drug particles might be responsible for the enhanced solubility and dissolution rate of repaglinide from its SD and to some extent in PMs. No endothermic peak of repaglinide was present in of SDs with PEG 6000 suggesting the absence of crystalline repaglinide. From FTIR spectroscopy, it was concluded that there was no well defined chemical interaction between repaglinide and PEG 6000 in SDs and in PMs, as no important new peaks could be observed.

The identical composition of Superdisintegrants showed that a substantial shorter time require for disintegration can be obtained and immediate release tablet...
were prepared. The repaglinide immediate release tablet (F2) showed 78.72% drug release within first 5 min. and 99.50% drug release within 30 min.

The results showed that the formulation satisfied the objective of fast disintegration, dissolution, % friability, hardness, wetting time, water absorption ratio, ease of administration and safety.

Success of the present study recommends a detailed investigation in to *in-vivo* studies for its effective use in clinical practice.
9. BIBLIOGRAPHY


25. Ishikawa T, Mukai B, Sriraishi S, Fuji M, Preparation of Rapidly disintegrating tablets using new types of Microcrystalline, line cellulose (PH-M series) and low substituted Hydroxy Propyl Cellulose or spherical sugar granules by direct compression method.


